The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition
Open accessAbstract
Dear Colleagues! We are glad to present the 9th Edition (revised) of Standards of Diabetes Care. These evidence-based guidelines were designed to standardize and facilitate diabetes care in all regions of the Russian Federation. The Standards are updated on the regular basis to incorporate new data and relevant recommendations from national and international clinical societies, including World Health Organization Guidelines (WHO, 2011, 2013), International Diabetes Federation (IDF, 2011, 2012, 2013), American Diabetes Association (ADA, 2018, 2019), American Association of Clinical Endocrinologists (AACE, 2019), International Society for Pediatric and Adolescent Diabetes (ISPAD, 2014, 2018) and Russian Association of Endocrinologists (RAE, 2011, 2012, 2015). Current edition of the Standards also integrates results of completed randomized clinical trials (ADVANCE, ACCORD, VADT, UKPDS, SAVOR, TECOS, LEADER, EXAMINE, ELIXA, SUSTAIN, DEVOTE, EMPA-REG OUTCOME, CANVAS, DECLARE, CARMELINA, REWIND, etc.), as well as findings from the national studies of diabetes mellitus (DM), conducted in close partnership with a number of Russian hospitals. Latest data indicates that prevalence of DM in the world increased during the last decade more than two-fold, reaching some 463 million patients by the end of 2019. According to the current estimation by the International Diabetes Federation, 578 million patients will be suffering from diabetes mellitus by by 2030 and 700 million by 2045. Like many other countries, Russian Federation experiences a sharp rise in the prevalence of DM. According to Russian Federal Diabetes Register, there are at least 4 584 575 patients with DM in this country by the end of 2018 (3,1% of population) with 92% (4 238 503) Type 2 DM, 6% (256 202) Type 1 DM and 2% (89 870) other types of DM, including 8 006 women with gestational DM. However, these results underestimates real quantity of patients, because they consider only registered cases. Results of Russian epidemiological study (NATION) con- firmed that only 54% of Type 2 DM are diagnosed. So real number of patients with DM in Russia is 9 million patients (about 6% of population). This is a great long-term problem, because a lot of patients are not diagnosed, so they dont receive any treatment ant have high risk of vascular complications. Severe consequences of the global pandemics of DM include its vascular complications: nephropathy, retinopathy, coronary, cerebral, coronary and peripheral vascular disease. These conditions are responsible for the majority of cases of diabetes-related disability and death. In сurrent edition of the Standards: New goals of glycemic control for the elderly, based on the presence of functional dependence, as well as for pregnant women, children and adolescents, are given. Added a snippet that describes the continuous glucose monitoring. Only low-density lipoprotein cholesterol level is used as a target for lipid metabolism. Proposes more stringent target levels of blood pressure. It also features updated guidelines on stratification of treatment in newly diagnosed Type 2 diabetes: the excess of the initial level of HbA1c over the target level was used as a criterion. In the recommendations for the personalization of the choice of antidiabetic agents, it is taken into account that in certain clinical situations (the presence of atherosclerotic cardiovascular diseases and their risk factors, chronic heart failure, chronic kidney disease, obesity, the risk of hypoglycemia) certain classes of hypoglycemic agents (or individual drugs) have proven advantages. Recommendations for psychosocial support are added. The position of metabolic surgery as a method of treatment of DM with morbid obesity is updated. Recommendations for diagnostic and treatment of hypogonadism syndrome in men with DM are added. For the first time, evidence levels of confidence and credibility levels of recommendations for diagnostic, therapeutic, rehabilitative and preventive interventions based on a systematic review of the literature are given in accordance with the recommendations of the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation. This text represents a consensus by the absolute majority of national experts, achieved through a number of fruitful discus- sions held at national meetings and forums. These guidelines are intended for endocrinologists, primary care physicians and other medical professionals involved in the treatment of DM. On behalf of the Working Group
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Authors/Task Force Members, Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A. A., Hasdai, D., Ohman, E. M., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm161 · Cited by 1,849
Mills, J. L., Conte, M. S., Armstrong, D. G., Pomposelli, F. B., Schanzer, A., Sidawy, A. N., & Andros, G. (2014) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2013.08.003 · Cited by 1,718
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia.
Weiss, M. D., Wasdell, M. B., Bomben, M. M., Rea, K., & Fréeman, R. D. (2006) · PubMed · doi:10.1097/01chi.0000205706.78818.ef · Cited by 1,216
Rubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G. M. M., Zimmet, P. Z., Del Prato, S., Ji, L., Sadikot, S. M., Herman, W. H., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0236 · Cited by 1,008
Skyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Fishman (2006) · doi:10.1097/01 · Cited by 547
Wanner, C., Lachin, J. M., Inzucchi, S. E., Fitchett, D., Mattheus, M., George, J., Woerle, H. J., Broedl, U. C., von Eynatten, M., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.117.028268 · Cited by 469
Busetto, L., Dicker, D., Azran, C., Batterham, R. L., Farpour-Lambert, N., Fried, M., Hjelmesæth, J., Kinzl, J., Leitner, D. R., Makaronidis, J. M., et al. (2017) · Obesity Facts · doi:10.1159/000481825 · Cited by 437
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
Wright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H., Lincoff, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.009 · Cited by 342
Schaper, N. C., Van Netten, J. J., Apelqvist, J., Lipsky, B. A., Bakker, K., & on behalf of the International Working Group on the Diabetic Foot (IWGDF) (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2695 · Cited by 334
Marx, N., Rosenstock, J., Kahn, S. E., Zinman, B., Kastelein, J. J., Lachin, J. M., Espeland, M. A., Bluhmki, E., Mattheus, M., Ryckaert, B., et al. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115570301 · Cited by 212
Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY. 8th edition
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Vikulova, O. K., Galstyan, G. R., Kuraeva, T. L., Peterkova, V. A., Smirnova, O. M., Starostina, E. G., Surkova, E. V., et al. (2017) · Diabetes mellitus · doi:10.14341/dm20171s8 · Cited by 199
Self-citationMetabolic surgery for the treatment of type 2 diabetes in obese individuals
Cummings, D. E., & Rubino, F. (2018) · Diabetologia · doi:10.1007/s00125-017-4513-y · Cited by 179
Dedov, I. I., Mel'nichenko, G. A., Shestakova, M. V., Troshina, E. A., Mazurina, N. V., Shestakova, E. A., Yashkov, Y. I., Neimark, A. E., Biryukova, E. V., Bondarenko, I. Z., et al. (2018) · Obesity and metabolism · doi:10.14341/omet2018153-70 · Cited by 173
Self-citationA review of human and analogue insulin trials
Gough, S. C. L. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.10.015 · Cited by 148
Shestakova, M. V., & Александровна, Ю. Е. (2015) · Diabetes Mellitus · doi:10.14341/dm20151s1-112 · Cited by 71
Self-citationMarso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P., Lange, M., Frandsen, K. B., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.06.004 · Cited by 69
Algorithms of Specialized Medical Care for Diabetes Mellitus Patients
Dedov, I. I., Shestakova, M. V., Александров, А. А., Galstyan, G. R., Grigoryan, O. R., Esayan, R. M., Kalashnikov, V. Y., Kuraeva, T. L., Lipatov, D. V., Mayorov, A. Y., et al. (2011) · Diabetes Mellitus · doi:10.14341/2072-0351-5612 · Cited by 53
Self-citationStandards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition)
Dedov, I. I., Shestakova, M. V., Александров, А. А., Galstyan, G. R., Grigoryan, O. R., Esayan, R. M., Kalashnikov, V. Y., Кураева, Т. Л., Липатов, Д. В., Mayorov, A. Y., et al. (2013) · Diabetes Mellitus · doi:10.14341/dm20131s1-121 · Cited by 38
Self-citationCLINICAL GUIDELINES FOR DIAGNOSIS AND TREATMENT OF DIABETIC FOOT SYNDROME
Galstyan, G. R., Tokmakova, A. Y., Egorova, D. N., Mitish, V. A., Paskhalova, Y. S., Antsiferov, M. B., Komelyagina, E., Удовиченко, О. В., Гурьева, И. В., Bregovskiy, V. B., et al. (2015) · Wounds and wound infections The prof B M Kostyuchenok journal · doi:10.17650/2408-9613-2015-2-3-63-83 · Cited by 32
Self-citationDedov, I. I., Shestakova, M. V., As, A., Анциферов, М. Б., Galstyan, G. R., Mayorov, A. Y., Mkrtumyan, A. M., Petunina, N. A., & Sukhareva, O. Y. (2015) · Diabetes Mellitus · doi:10.14341/dm201515-23 · Cited by 18
Self-citationRossiyskiy konsensus po terapii sakharnogo diabeta u detey i podrostkov
Dedov, I. I., Peterkova, V. A., & Кураева, Т. Л. (2010) · Diabetes Mellitus · doi:10.14341/2072-0351-6048 · Cited by 14
Self-citationDedov, I. I., Shestakova, M. V., Абусуев, С. А., Valeeva, F. V., Verbovoy, A. F., Galstyan, G. R., Dogadin, S. A., Karpova, I. A., Mayorov, A. Y., Suntsov, Y. I., et al. (2010) · Diabetes Mellitus · doi:10.14341/2072-0351-6049 · Cited by 13
Self-citation
Cited by
Arterial hypertension in adults. Clinical guidelines 2020
Kobalava, Z. D., Konradi, A. O., Nedogoda, S. V., Shlyakhto, E. V., Arutyunov, G. P., Baranova, E. I., Barbarash, O. L., Boitsov, S. A., Vavilova, T. V., Villevalde, S. V., et al. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-3-3786 · Cited by 541
Self-citation
Metadata
- Authors
- Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Vikulova, O. K., Galstyan, G. R., Kuraeva, T. L., Peterkova, V. A., Smirnova, O. M., Starostina, E. G., Surkova, E. V., Sukhareva, O. Y., Tokmakova, A. Y., Shamkhalova, M. S., Jarek-Martynova, I. R., Artemova, E. V., Beshlieva, D. D., Bondarenko, O. N., Volevodz, N. N., Grigoryan, O. R., Gomova, I. S., Dzhemilova, Z. N., Esayan, R. M., Ibragimova, L. I., Kalashnikov, V. Y., Kononenko, I. V., Laptev, D. N., Lipatov, D. V., Motovilin, O. G., Nikonova, T. V., Rozhivanov, R. V., & Shestakova, E. A.
- Venue
- Diabetes mellitus
- Publisher
- Endocrinology Research Centre
- Published
- 2019-12-03
- Volume
- 22
- Issue
- 1S1
- Pages
- 1-121
- ISSN
- 2072-0351 (ISSN-L)
- 2072-0378
- OpenAlex
- W2995731459
- Cited by
- 257
- References
- 36
- Type
- book review
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.